Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac N.V (CVAC) EBT: 2019-2025

Historic EBT for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to -$67.9 million.

  • CureVac N.V's EBT rose 11.52% to -$67.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $243.5 million, marking a year-over-year increase of 181.54%. This contributed to the annual value of $204.0 million for FY2024, which is 172.92% up from last year.
  • Per CureVac N.V's latest filing, its EBT stood at -$67.9 million for Q2 2025, which was down 24.93% from -$54.3 million recorded in Q1 2025.
  • Over the past 5 years, CureVac N.V's EBT peaked at $318.6 billion during Q2 2021, and registered a low of -$467.1 billion during Q4 2021.
  • Over the past 3 years, CureVac N.V's median EBT value was -$64.8 million (recorded in 2023), while the average stood at -$19.0 million.
  • Examining YoY changes over the last 5 years, CureVac N.V's EBT showed a top increase of 394,901,389.71% in 2021 and a maximum decrease of 684,175.84% in 2021.
  • Quarterly analysis of 5 years shows CureVac N.V's EBT stood at -$467.1 billion in 2021, then soared by 99.97% to -$131.4 million in 2022, then rose by 29.16% to -$93.1 million in 2023, then skyrocketed by 55.72% to -$41.2 million in 2024, then rose by 11.52% to -$67.9 million in 2025.
  • Its EBT stands at -$67.9 million for Q2 2025, versus -$54.3 million for Q1 2025 and -$41.2 million for Q4 2024.